Cargando…
Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency
Hyperargininemia in patients with arginase 1 deficiency (ARG1‐D) is considered a key driver of disease manifestations, including spasticity, developmental delay, and seizures. Pegzilarginase (AEB1102) is an investigational enzyme therapy which is being developed as a novel arginine lowering approach...
Autores principales: | Diaz, George A., Schulze, Andreas, McNutt, Markey C., Leão‐Teles, Elisa, Merritt, J. Lawrence, Enns, Gregory M., Batzios, Spyros, Bannick, Allison, Zori, Roberto T., Sloan, Leslie S., Potts, Susan L., Bubb, Gillian, Quinn, Anthony G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359196/ https://www.ncbi.nlm.nih.gov/pubmed/33325055 http://dx.doi.org/10.1002/jimd.12343 |
Ejemplares similares
-
Arginase 1 Deficiency in Patients Initially Diagnosed with Hereditary Spastic Paraplegia
por: McNutt, Markey C., et al.
Publicado: (2022) -
Clinical status, biochemical profile and management of a single cohort of patients with arginase deficiency
por: Keshavan, Nandaki, et al.
Publicado: (2021) -
SAT079 A Novel Variant In The Carboxyl Ester Lipase (CEL) Gene Causing MODY
por: Medavarapu, chalapathi Rao, et al.
Publicado: (2023) -
Natural history of arginase 1 deficiency and the unmet needs of patients: A systematic review of case reports
por: Bin Sawad, Aseel, et al.
Publicado: (2022) -
Arginase and pulmonary diseases
por: Maarsingh, Harm, et al.
Publicado: (2008)